Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

被引：2

作者：

Nitz, Ulrike ^{[1
,2
]}

Gluz, Oleg ^{[1
,2
]}

Kates, Ronald E. ^{[1
]}

Hofmann, Daniel ^{[1
]}

Kreipe, Hans H. ^{[3
]}

Christgen, Matthias ^{[3
]}

Shak, Steve ^{[4
]}

Clemens, Michael ^{[5
]}

Kraemer, Stefan

Aktas, Bahriye ^{[6
]}

Kuemmel, Sherko ^{[7
]}

Reimer, Toralf ^{[8
]}

Kusche, Manfred ^{[9
]}

Heyl, Volker ^{[10
]}

Lorenz-Salehi, Fatemah ^{[11
]}

Just, Marianne ^{[12
]}

Liedtke, Cornelia ^{[1
,13
]}

Wuerstlein, Rachel ^{[1
,14
]}

Harbeck, Nadia ^{[1
,14
]}

机构：

[1] West German Study Grp, Dusseldorf, Germany

[2] Ev Hosp Bethesda, Breast Ctr Niederrhein, Monchengladbach, Germany

[3] Hannover Med Sch, Inst Pathol, Hannover, Germany

[4] Genom Hlth Inc, Redwood City, CA USA

[5] Breast Ctr, Mutterhaus Borromaerinnen, Trier, Germany

[6] Univ Clin Essen, Women Clin, Essen, Germany

[7] Clin Essen Mitte, Women Clin, Essen, Germany

[8] Clin Suedstadt, Rostock, Germany

[9] Marien Hosp Aachen, Women Clin, Aachen, Germany

[10] Asklepios Paulinen Clin, Wiesbaden, Germany

[11] Dr Horst Schmidt Clin, Women Clin, Wiesbaden, Germany

[12] Oncol Practice, Bielefeld, Germany

[13] Univ Clin Schleswig Holstein, Kiel, Germany

[14] LMU, Univ Clin Grosshadern, Breast Ctr, Munich, Germany

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

10.1158/1538-7445.SABCS14-P4-11-01

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P4-11-01

引用

页数：2

共 36 条

[31] Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial
Ulrike Nitz
Oleg Gluz
Matthias Christgen
Ronald E. Kates
Michael Clemens
Wolfram Malter
Benno Nuding
Bahriye Aktas
Sherko Kuemmel
Toralf Reimer
Andrea Stefek
Fatemeh Lorenz-Salehi
Petra Krabisch
Marianne Just
Doris Augustin
Cornelia Liedtke
Calvin Chao
Steven Shak
Rachel Wuerstlein
Hans H. Kreipe
Nadia Harbeck
Breast Cancer Research and Treatment, 2019, 175 : 265 - 266
[32] WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Hofmann, Daniel
Nitz, Ulrike
Gluz, Oleg
Kates, Ronald E.
Schinkoethe, Timo
Staib, Peter
Harbeck, Nadia
TRIALS, 2013, 14
[33] WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
Daniel Hofmann
Ulrike Nitz
Oleg Gluz
Ronald E Kates
Timo Schinkoethe
Peter Staib
Nadia Harbeck
Trials, 14
[34] ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL
Piccolo, F.
Pappagallo, G.
Zambelli, A.
Caputo, A.
VALUE IN HEALTH, 2019, 22 : S503 - S503
[35] Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial (vol 165, pg 573, 2017)
Nitz, Ulrike
Gluz, Oleg
Christgen, Matthias
Kates, Ronald E.
Clemens, Michael
Malter, Wolfram
Nuding, Benno
Aktas, Bahriye
Kuemmel, Sherko
Reimer, Toralf
Stefek, Andrea
Lorenz-Salehi, Fatemeh
Krabisch, Petra
Just, Marianne
Augustin, Doris
Liedtke, Cornelia
Chao, Calvin
Shak, Steven
Wuerstlein, Rachel
Kreipe, Hans H.
Harbeck, Nadia
BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 265 - 266
[36] Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (vol 21, pg 1443, 2020)
Smith, I
Robertson, J.
Kilburn, L.
LANCET ONCOLOGY, 2020, 21 (12): : E553 - E553

← 1 2 3 4 →